{"id":390893,"date":"2017-10-04T00:00:00","date_gmt":"2017-10-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrmd0018-2017-biopharma-diabetic-nephropathy-current-treatment-physician-insights-us-2017\/"},"modified":"2026-04-27T23:42:19","modified_gmt":"2026-04-27T23:42:19","slug":"cutrmd0018-2017-biopharma-diabetic-nephropathy-current-treatment-physician-insights-us-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrmd0018-2017-biopharma-diabetic-nephropathy-current-treatment-physician-insights-us-2017\/","title":{"rendered":"Diabetic Nephropathy | Current Treatment: Physician Insights | US | 2017"},"content":{"rendered":"<p>Diabetic nephropathy (<abbr title=\"diabetic nephropathy\">DN<\/abbr>) refers to kidney disease caused by diabetes. <abbr title=\"diabetic nephropathy\">DN<\/abbr> is a leading cause of chronic kidney disease (<abbr title=\"chronic kidney disease\">CKD<\/abbr>), and is associated with high morbidity, mortality, and cost. Use of pharmacotherapy for <abbr title=\"diabetic nephropathy\">DN<\/abbr> varies by disease severity, physician specialty, and <abbr title=\"chronic kidney disease\">CKD<\/abbr> stage. Physicians consider management of <abbr title=\"diabetic nephropathy\">DN<\/abbr> challenging because current therapies manage only the complications of <abbr title=\"diabetic nephropathy\">DN<\/abbr>. Currently available therapies have limited efficacy, are unable to treat the underlying disease, and prevent progressive renal decline in patients. Our Current Treatment deep dive content investigates the current prescribing practices for <abbr title=\"diabetic nephropathy\">DN<\/abbr> and focuses on the various factors driving the these treatment decisions.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>Do treatment decisions for <abbr title=\"diabetic nephropathy\">DN<\/abbr> differ based on disease progression and the specialty of the treating physician?<\/li>\n<li>Which attributes are most important in choosing drugs for the management of <abbr title=\"diabetic nephropathy\">DN<\/abbr> patients?<\/li>\n<li>How do physicians perceive standard of care therapies such as <abbr title=\"angiotensin-converting enzyme\">ACE<\/abbr> inhibitors or <abbr title=\"angiotensin receptor blocker\">ARB<\/abbr>s for <abbr title=\"diabetic nephropathy\">DN<\/abbr>?<\/li>\n<li>What is the level of satisfaction among physicians with currently available <abbr title=\"diabetic nephropathy\">DN<\/abbr> treatments? What is the level of familiarity and interest in products in the development pipeline?<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390893","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-diabetic-nephropathy","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390893\/revisions"}],"predecessor-version":[{"id":394017,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390893\/revisions\/394017"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}